News articles in the US "speculate" that medicare may not cover provenge is typical of media beat ups.
IMO the US cannot afford to have such a major medical milestone put aside to the many prostrate cancer sufferes. This would be akin to not supporting a new and proven technology for breast cancer.
IMO PRR is on the verge of a new paradigm in medical approach to a range of immunological diseases.
As soon as this speculation DNDN will bounce significantly.
from a market point of view the price of DNDN fluctuations is trader and risk driven.
PRR at present represents an outstanding co with very bright future imo
us medicare
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.020(7.41%) |
Mkt cap ! $421.8M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 29.5¢ | 27.0¢ | $1.138M | 3.985M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 63444 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 65000 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |